Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)

CCBT has shown potential efficacy in steroid-refractory GI aGvHD, and given the observed ORR when used as second-line therapy, CCBT could serve as an acceptable alternative for patients who are ruxolitinib-intolerant. Ruxolitinib-refractory GI GvHD remains an area of unmet need and CCBT can provide salvage therapy for some patients.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2024-11-22
DOI
https://doi.org/10.3390/cancers16233912
Citations
1
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)

Eileen Smith, Vaibhav Agrawal, Anthony S. Stein, Amanda Blackmon et al.
1 citations
Cancers
Hematopoietic Stem Cell Transplantation
0.45
article

Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)

Eileen Smith, Vaibhav Agrawal, Anthony S. Stein, Amanda Blackmon, Tina Nguyen, Ahmed Aribi, Ibrahim Taha Aldoss, Monzr M. Al Malki, Pamela S. Becker, Shukaib Arslan, Andrew Artz, Brian Ball, Guido Marcucci, Peter Curtin, Amandeep Salhotra, Paul Koller, Haris Ali, Hoda Pourhassan, Forrest Stewart, Salman Otoukesh, Idoroenyi Amanam, Ryotaro Nakamura, Dongyun Yang, Stephen J. Forman
article en
1 citations

Abstract

CCBT has shown potential efficacy in steroid-refractory GI aGvHD, and given the observed ORR when used as second-line therapy, CCBT could serve as an acceptable alternative for patients who are ruxolitinib-intolerant. Ruxolitinib-refractory GI GvHD remains an area of unmet need and CCBT can provide salvage therapy for some patients.

CancersVol. 16(23)
City Of Hope National Medical Center (US)
Good health and well-being
Openalex Percentile: Top 31%
Hematopoietic Stem Cell Transplantation
0.45
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.